Praziquantel

Exact identity, dog use and dose are supported by current Georgian and Moldovan registrations plus manufacturer instructions; identical-strength EU dog products provide a strong narrower regulatory control. No exact international regulator SPC or public modern assessment supports the much broader Giardia/trematode/prevention claims.

Praziquantel/pyrantel/fenbendazole at 5/14.4/20 mg/kg has a current identical-strength EU dog authorisation for defined mixed GI nematode+cestode stages, so that narrower core is credible. The manufacturer extends one dose to larval stages, Strongyloides, prevention, several trematodes and Giardia without direct exact-product outcomes; a single 20 mg/kg fenbendazole exposure is not a guideline Giardia course.

The manufacturer reports no signs at 3-5x dose and twice-duration exposure in dogs, and the active classes are generally well tolerated. Confidence is limited by no independent exact safety report, broad organ/illness/reproductive exclusions and cholinergic interactions; GI or nonspecific reactions remain possible.

One dose, no fasting, direct/food administration, quarter scoring and individual sachets are convenient. Accurate weighing and deliverable quarter increments remain necessary above 10 kg; repeat/quarterly prevention requires a parasite-risk plan rather than automatic calendar use.

Exact local cat registration and manufacturer directions are corroborated by Moldova; authorised EU cat/dog three-active products exist but differ in fenbendazole strength/presentation. No exact internationally regulated feline bridge or public assessment supports the full extended scope.

Praziquantel and pyrantel support important feline cestode/nematode endpoints, and other regulated cat/dog triple products support class plausibility. However, no exact-composition feline outcome/authorisation bridge validates the one-dose broad larval, Strongyloides, trematode, prevention or Giardia scope; weight bands also create variable exposure in small cats.

The manufacturer explicitly states cats are more overdose-sensitive and may develop depression, vomiting or diarrhoea, without a specific antidote. Quarter-band exposure rises at the low end, and age, periparturient, organ-disease, illness/debilitation and cholinergic-interaction exclusions materially narrow safe use.

One dose, no fasting, food administration and quarter scoring help, including 1-2.5 kg cats. Small-bodyweight bands create relatively large exposure steps, exact quartering/ingestion must be confirmed and feline overdose sensitivity makes rounding or unsupervised repeating unacceptable.

The exact presentation is registered in Georgia (000695, valid to 2029) with a 2024 Russian manufacturer instruction; no EU, UK or US authorisation was documented in the reviewed evidence, but praziquantel itself is among the best-documented anthelmintics.

Praziquantel at 5 mg/kg (1 tablet per 10 kg) is highly effective against Taenia, Dipylidium and Echinococcus and is the ESCCAP and WSAVA reference cestocide; it has no effect on roundworms, and this generic's bioequivalence is not public.

Praziquantel has a wide margin; the label excludes puppies under 3 weeks and animals with marked liver or kidney disease, emaciation or infection, and asks for veterinary supervision in pregnancy and lactation.

Tablets for dogs from 5 kg are simple, but smaller dogs need half a tablet crushed in 5 ml of water and given at 1 ml/kg straight away, which is fiddly.

The exact presentation is registered in Georgia (000695, valid to 2029) with a 2024 Russian manufacturer instruction; no EU, UK or US authorisation was documented in the reviewed evidence, but praziquantel itself is among the best-documented anthelmintics.

Praziquantel at 5 mg/kg is highly effective against Dipylidium, Taenia taeniaeformis and Echinococcus in cats and is the ESCCAP reference cestocide; it has no effect on roundworms, and bioequivalence is not public.

Praziquantel has a wide margin in cats, although its bitter taste can cause salivation; the label excludes kittens under 3 weeks and animals with marked liver or kidney disease and asks for supervision in pregnancy and lactation.

Most cats are under 5 kg and need half a tablet crushed in 5 ml of water and given at 1 ml/kg straight away, which is fiddly and often refused.

The exact presentation is registered in Georgia (000903, valid to 2030) with a 2024 Russian manufacturer instruction, but no EU, UK or US authorisation was documented in the reviewed evidence or product-specific study.

Praziquantel and pyrantel pamoate at 1 tablet per 10 kg are well supported against tapeworms including Echinococcus, Toxocara and hookworms, but pyrantel does not cover Trichuris whipworms.

The combination has a wide margin; the label excludes puppies under 3 weeks and animals with marked liver or kidney disease and asks for supervision in pregnancy and lactation, but no independent safety data exist.

Tablets for dogs from 5 kg are simple, but smaller dogs need half a tablet crushed in 5 ml of water and given at 1 ml/kg straight away.

The exact presentation has a valid central EU authorisation and a current UPD record, supported by detailed official product information and a mature EPAR. It is not registered in Georgia or the US; the separate GB national authorisation expired on 3 July 2026, while EU authorisation including Northern Ireland remains valid.

Controlled and multicentre field evidence supports high activity across fleas, major gastrointestinal helminths, lungworms, eyeworm and heartworm prevention. The label is deliberately restricted to simultaneous three-group need; tick protection is shorter than flea protection, and some parasite-specific follow-up or repeat dosing remains necessary.

Correct topical use is generally well tolerated and has a wide experimental safety margin, but common local coat or skin changes and salivation can occur. Accidental licking can cause gastrointestinal or transient neurological signs; very rare tremor or visual impairment, reproductive uncertainty and important species and health restrictions require counselling.

One whole applicator gives broad single-dose coverage and is easier than several separate products, but it must reach the skin at an inaccessible neck site, the cat must not be bathed for two days, exact weight-band selection is required and cats above 7.5 kg need a veterinarian-selected applicator combination.

The exact presentation has a valid central EU authorisation and a current UPD record, supported by detailed official product information and a mature EPAR. It is not registered in Georgia or the US; the separate GB national authorisation expired on 3 July 2026, while EU authorisation including Northern Ireland remains valid.

Controlled and multicentre field evidence supports high activity across fleas, major gastrointestinal helminths, lungworms, eyeworm and heartworm prevention. The label is deliberately restricted to simultaneous three-group need; tick protection is shorter than flea protection, and some parasite-specific follow-up or repeat dosing remains necessary.

Correct topical use is generally well tolerated and has a wide experimental safety margin, but common local coat or skin changes and salivation can occur. Accidental licking can cause gastrointestinal or transient neurological signs; very rare tremor or visual impairment, reproductive uncertainty and important species and health restrictions require counselling.

One whole applicator gives broad single-dose coverage and is easier than several separate products, but it must reach the skin at an inaccessible neck site, the cat must not be bathed for two days, exact weight-band selection is required and cats above 7.5 kg need a veterinarian-selected applicator combination.

Exact composition, N10 presentation, Georgian authorisation 000180, basic dose and core restrictions are current and verifiable. However the exact manufacturer brochure, live product page and catalogue disagree on the full parasite spectrum, contraindications and interaction detail; no internationally recognised exact-product authorisation dossier or controlled formulation outcome was found.

Praziquantel 5 mg/kg has a credible cestode bridge and ivermectin/levamisole have susceptible-parasite activity, but no controlled exact-combination outcome was found. The single 200-microgram/kg ivermectin exposure does not validate the unusually broad flea, hard-tick, trematode, demodicosis or unqualified Dirofilaria claims; independent demodicosis guidance uses daily titrated macrocyclic-lactone courses and the FDA comparator explicitly does not treat adult heartworms or clear microfilariae.

In a correctly screened non-ABCB1 adult dog, component doses are pharmacologically plausible, but the exact ivermectin exposure is 200 micrograms/kg—16 times the FDA comparator's maximum 12.5 micrograms/kg and within the exact leaflet's own 100-500 micrograms/kg intoxication range for susceptible dogs. Combined levamisole toxicity, broad interaction restrictions, contraindicated pregnancy/debilitation/infection and absent exact safety margins or adverse-event frequencies keep safety weak.

A single crushed tablet per 10 kg in adult dogs and an N10 pack are simple when the endpoint and patient are appropriate. Practicality falls because complete intake of the medicated food must be verified, dogs below 1.5 years need divided dosing, small dogs may require less than the half-tablet score, demodicosis needs repeat treatment and monitoring, and safe selection may require ABCB1 and heartworm assessment.

The exact composition, species, route and current dose table are documented by two European regulatory sources and the product has active Georgian veterinary registration (203-11); independent formulation-specific outcome evidence is limited.

The fenbendazole-praziquantel combination covers common susceptible roundworms and tapeworms, but efficacy depends on correct parasite identification, label schedule and local susceptibility rather than the brand name alone.

The reviewed exact label lists no contraindications or known adverse effects and permits use in labelled breeding schedules; correct dosing and individual hypersensitivity precautions still apply.

A flavoured, crushable, cross-scored tablet with quarter-tablet dog bands and usually single-dose administration is highly workable across a broad weight range.

The exact composition, feline indication, route and current dose table are documented by two European regulatory sources and the product has active Georgian veterinary registration (203-11); independent exact-formulation evidence is limited.

The combination provides useful labelled roundworm and tapeworm coverage in cats, subject to correct parasite diagnosis and the product-specific schedule.

The exact label reports no known adverse effects at the recommended dose, but notes transient nausea, vomiting or diarrhoea after overdose and greater feline sensitivity than in dogs.

Quarter-tablet dosing, crushability and a usually single administration are practical; the fixed three-quarter-tablet band above 4 kg still requires strict adherence to this product label.

The exact formulation is registered in Georgia and supported by a current Czech competent-authority or EU product dossier.

Fenbendazole, pyrantel and praziquantel provide rational broad intestinal nematode and cestode coverage; component and related-combination evidence is established, but robust independent trials of this exact three-drug product are limited.

The labelled safety profile is generally favourable, but piperazine or unplanned anthelmintic overlap, hepatic disease, pregnancy restrictions and dose-band limits require attention.

The graduated paste supports small-patient dosing and direct oral delivery, but accurate weighing, applicator measurement and complete swallowing remain essential.

The exact formulation is registered in Georgia and supported by a current Czech competent-authority or EU product dossier.

Fenbendazole, pyrantel and praziquantel provide rational broad intestinal nematode and cestode coverage; component and related-combination evidence is established, but robust independent trials of this exact three-drug product are limited.

The labelled safety profile is generally favourable, but piperazine or unplanned anthelmintic overlap, hepatic disease, pregnancy restrictions and dose-band limits require attention.

The graduated paste supports small-patient dosing and direct oral delivery, but accurate weighing, applicator measurement and complete swallowing remain essential.

A current official Czech package leaflet verifies the exact formulation and dose bands, supported by active Georgian veterinary registration (194-11/226-11); independent formulation-specific evidence remains limited.

The three-drug combination supplies broad susceptible nematode and cestode coverage, but outcome depends on parasite diagnosis and label-concordant dosing.

A wide margin is described after overdose, but liver damage, ocular cysticercosis, spinal neurocysticercosis, hypersensitivity and prohibited antiparasitic combinations require patient selection.

Usually single-dose, scored oral administration is workable, but the forte tablet has no labelled dog dose below 2 kg and rounds every started 10 kg above 10 kg.

A current official Czech leaflet verifies the exact feline formulation and dose, supported by active Georgian veterinary registration (194-11/226-11); independent exact-formulation evidence is limited.

The combination offers broad susceptible intestinal nematode and cestode coverage within its narrow labelled feline weight band.

The label reports a wide overdose margin, but the same liver, cysticercosis, hypersensitivity and combination restrictions apply.

A single half-tablet dose is simple for 2-5 kg cats, but no dose is established on this forte label below 2 kg or above 5 kg, materially narrowing practical use.

The exact formulation is registered in Georgia and supported by a current Czech competent-authority or EU product dossier.

Fenbendazole, pyrantel and praziquantel provide rational broad intestinal nematode and cestode coverage; component and related-combination evidence is established, but robust independent trials of this exact three-drug product are limited.

The labelled safety profile is generally favourable, but piperazine or unplanned anthelmintic overlap, hepatic disease, pregnancy restrictions and dose-band limits require attention.

The small scored tablet is useful for puppies, small dogs and cats, but its labelled weight bands are narrow and exact weighing is essential.

The exact formulation is registered in Georgia and supported by a current Czech competent-authority or EU product dossier.

Fenbendazole, pyrantel and praziquantel provide rational broad intestinal nematode and cestode coverage; component and related-combination evidence is established, but robust independent trials of this exact three-drug product are limited.

The labelled safety profile is generally favourable, but piperazine or unplanned anthelmintic overlap, hepatic disease, pregnancy restrictions and dose-band limits require attention.

The small scored tablet is useful for puppies, small dogs and cats, but its labelled weight bands are narrow and exact weighing is essential.

The exact product is registered in Georgia and has a current EU multi-country dossier.

The praziquantel-pyrantel combination has long regulatory use and controlled evidence of high efficacy against susceptible feline cestodes and nematodes, including direct Drontal-combination data.

Adverse effects are generally rare and transient, but kittens under six weeks, pregnancy restrictions, hypersensitivity and piperazine co-administration must be respected.

A scored chewable tablet permits half-tablet dosing and simple single administration after accurate weighing.

The exact three-drug product, current SPC dose table and authorisation are documented in the EU database, with active Georgian veterinary registration (299-11).

The labelled praziquantel-pyrantel-fenbendazole combination provides useful broad coverage of susceptible canine intestinal nematodes and cestodes with a product-specific regimen.

The label-defined restrictions are manageable but relevant: do not use below 4 weeks, with piperazine or in hypersensitive animals; routine antiparasitic stewardship remains necessary.

The palatable chewable tablet can be quartered, given with or without food and is usually administered once across clear weight bands.

The exact product is registered in Georgia (002547) by a Georgian manufacturer with a current distributor instruction, but the registration expires on 2 November 2026, the English text carries a known dosing error and no EU, UK or US authorisation was documented in the reviewed evidence or product study.

Praziquantel and pyrantel are well supported at 1 tablet per 10 kg, but fenbendazole is only 20 mg/kg as a single dose, well below EU single-dose fenbendazole combinations, so its added whipworm and roundworm effect is uncertain.

Pyrantel and fenbendazole are well tolerated and use is allowed from 3 weeks, but the instruction gives no pregnancy guidance and no independent safety data exist.

The Georgian label gives practical bands up to 50 kg, but the 20-30 kg band is missing and quarter-tablet doses for dogs under 2 kg are hard to measure.

The exact strength is actively registered in Georgia and the same-manufacturer current UK Krka Wormer SPC matches the formulation and target species. The public foreign document uses an alternate trade name, slightly reducing exact-brand transparency.

Praziquantel-pyrantel is a mature single-dose feline combination with controlled trial support against susceptible nematodes and cestodes. The label is species- and stage-specific, and reinfection or persistent ascarids may require reassessment rather than unplanned repeat dosing.

Mild transient gastrointestinal or neurologic signs are extremely rare. Pregnancy, kittens under six weeks, weight below 1 kg, hypersensitivity and piperazine or unsupervised dewormer combinations remain important exclusions.

One single scored tablet per 4 kg with half-tablet steps is straightforward from 1-8 kg and can be given directly or in a little food. Dosing outside that range is not established and the tablet is not documented as palatable or crushable.

The exact presentation is actively registered in Georgia. Clinical instructions use the same-manufacturer, same-strength current UK Krka Multiwormer SPC rather than a public document carrying the Dehinel trade name, so exact-brand transparency is one step below Drontal.

The established febantel-pyrantel-praziquantel combination has strong class and field support for susceptible canine intestinal nematodes and cestodes. This exact label is narrower than Drontal Tasty: no whipworm, Echinococcus or Giardia claim should be imported.

Very rare transient gastrointestinal or nonspecific signs are expected, but the first two-thirds of pregnancy, age under two weeks, weight below 2 kg, piperazine, cholinergic and selected interacting drugs require explicit screening.

The flavoured cross-scored tablet supports quarter-tablet dosing from just over 2 kg through 40 kg and can be given directly or with food. It has no labelled dose above 40 kg and should not be extrapolated.

The current AVZ instruction describes a cat-only product, while the Georgian register entry (000694, valid to 2029) lists dogs; no EU, UK or US authorisation was documented in the reviewed evidence and no product-specific study.

Praziquantel and pyrantel are well supported against feline tapeworms and roundworms, and low-dose monthly ivermectin is an established feline heartworm preventive class; product-level dose evidence and bioequivalence are not public.

Ivermectin at preventive doses is well tolerated in cats, but the label bans pregnancy, lactation and other anthelmintics, and no independent safety data exist.

One tablet with the morning feed is simple for deworming, but monthly seasonal heartworm use depends on reliable pilling of cats.

The exact presentation is registered in Georgia (000698, valid to 2029) with a 2017 Russian manufacturer instruction, but no EU, UK or US authorisation was documented in the reviewed evidence and no product-specific study.

Praziquantel and pyrantel are well supported against tapeworms, Toxocara and hookworms, and low-dose monthly ivermectin is an established heartworm preventive; no component treats Trichuris, and product-level evidence is not public.

Preventive-dose ivermectin is generally tolerated, but in heartworm-positive dogs with many microfilariae it can trigger shock-like reactions, and MDR1-mutant breeds need supervision; pregnancy and lactation are excluded.

A scored tablet with the morning feed and no fasting is practical, but heartworm prevention needs monthly dosing through the mosquito season and a test before starting.

The exact presentation is registered in Georgia (000696, valid to 2029) with a 2017 Russian manufacturer instruction, but no EU, UK or US authorisation was documented in the reviewed evidence and no product-specific study.

Praziquantel and pyrantel are well supported against tapeworms, Toxocara and hookworms, and low-dose monthly ivermectin is an established heartworm preventive; no component treats Trichuris, and product-level evidence is not public.

Preventive-dose ivermectin is generally tolerated, but in heartworm-positive dogs with many microfilariae it can trigger shock-like reactions, and MDR1-mutant breeds need supervision; pregnancy and lactation are excluded.

A scored tablet with the morning feed and no fasting is practical, but heartworm prevention needs monthly dosing through the mosquito season and a test before starting.

The exact bone-shaped 150/144/50 mg presentation is actively registered in Georgia and has a current exact HPRA SPC plus a multi-country EU authorisation trail.

The full helminth label is supported by recent exact-brand field evidence and longer controlled field data. A small randomized trial supports the three-day Giardia claim, but incomplete clearance in some dogs and diagnostic uncertainty prevent treating every diarrhoeic dog empirically.

Adverse events are very rare and usually mild/transient, but early pregnancy is contraindicated, cholinergic or piperazine combinations can be hazardous, and resistance or underdosing remains possible.

The palatable bone-shaped tablet is voluntarily accepted by most tested dogs, divides into halves, works with or without food and follows a simple 1-tablet/10-kg rule. A retained half is limited to seven days and Giardia requires three doses.

The exact product has a mature current UK/EU regulatory dossier, but an exact Georgian cat-product registration was not found; the former 21-11 mapping was a Frontline product-ID collision.

The praziquantel-pyrantel combination has long regulatory use and controlled evidence of high efficacy against susceptible feline cestodes and nematodes, including direct Drontal-combination data.

Adverse effects are generally rare and transient, but kittens under six weeks, pregnancy restrictions, hypersensitivity and piperazine co-administration must be respected.

A scored film-coated tablet permits half-tablet dosing and single administration, although it is not documented as crushable or flavoured.

The exact strength and presentation are actively registered in Georgia and supported by an exact HPRA SPC. The dossier is transparent, although its cited revision is older than the newest Tasty formulation label.

The three-drug combination has controlled and field evidence against susceptible canine intestinal nematodes and cestodes and the exact label covers adult and selected immature stages. It does not replace diagnosis, risk-based scheduling or intermediate-host control.

Adverse effects are very rare and usually mild/transient, with useful overdose tolerance. Piperazine and cholinergic combinations, pregnancy dosing, hypersensitivity, minimum weight and human Echinococcus risk still require safeguards.

A single flavoured half-tablet-step dose can be given directly or with food without fasting and extends above 40 kg by the labelled 1-tablet/10-kg rule. It is unsuitable below 3 kg and unused parts must be discarded.

The exact strengths are registered in Georgia and have valid EU national-authorisation records and official product information.

Mebendazole and praziquantel are established anthelmintics with rational nematode/cestode coverage, but accessible independent efficacy evidence for these exact paste products and their full claimed parasite spectrum is sparse.

The official leaflet reports no known adverse effects but identifies hypersensitivity and organophosphate ectoparasiticide overlap as contraindications; limited modern product-specific safety literature constrains confidence.

A graduated syringe supports accurate oral dosing, but weighing and measurement must be precise and the labelled course requires administration on three consecutive days.

The exact strengths are registered in Georgia and have valid EU national-authorisation records and official product information.

Mebendazole and praziquantel are established anthelmintics with rational nematode/cestode coverage, but accessible independent efficacy evidence for these exact paste products and their full claimed parasite spectrum is sparse.

The official leaflet reports no known adverse effects but identifies hypersensitivity and organophosphate ectoparasiticide overlap as contraindications; limited modern product-specific safety literature constrains confidence.

A graduated syringe supports accurate oral dosing, but weighing and measurement must be precise and the labelled course requires administration on three consecutive days.

The exact strengths are registered in Georgia and have valid EU national-authorisation records and official product information.

Mebendazole and praziquantel are established anthelmintics with rational nematode/cestode coverage, but accessible independent efficacy evidence for these exact paste products and their full claimed parasite spectrum is sparse.

The official leaflet reports no known adverse effects but identifies hypersensitivity and organophosphate ectoparasiticide overlap as contraindications; limited modern product-specific safety literature constrains confidence.

A graduated syringe supports accurate oral dosing, but weighing and measurement must be precise and the labelled course requires administration on three consecutive days.

The exact strengths are registered in Georgia and have valid EU national-authorisation records and official product information.

Mebendazole and praziquantel are established anthelmintics with rational nematode/cestode coverage, but accessible independent efficacy evidence for these exact paste products and their full claimed parasite spectrum is sparse.

The official leaflet reports no known adverse effects but identifies hypersensitivity and organophosphate ectoparasiticide overlap as contraindications; limited modern product-specific safety literature constrains confidence.

A graduated syringe supports accurate oral dosing, but weighing and measurement must be precise and the labelled course requires administration on three consecutive days.

The exact 7 ml presentation is registered in Georgia (000234, valid to 2028) with a 2017 Russian manufacturer instruction, but no EU, UK or US authorisation was documented in the reviewed evidence, and albendazole is not an authorised small-animal anthelmintic in those markets.

Praziquantel at 5 mg/kg is well supported against feline tapeworms, but the roundworm component rests on albendazole, which has little controlled feline evidence compared with pyrantel, emodepside or milbemycin.

Albendazole has caused bone-marrow suppression in a cat and a dog and is teratogenic; the label bans pregnancy, lactation, kittens under 3 weeks and debilitated or infected animals.

A measured liquid at 1 ml/kg is easier than tablets for kittens and many cats, and the label explains dilution for animals under 0.5 kg.

The exact 10 ml presentation is registered in Georgia (000236, valid to 2028) with a 2017 Russian manufacturer instruction, but no EU, UK or US authorisation was documented in the reviewed evidence, and albendazole is not an authorised small-animal anthelmintic in those markets.

Praziquantel at 5 mg/kg is well supported against tapeworms, but the roundworm component rests on albendazole, which has little controlled canine evidence compared with febantel, fenbendazole or pyrantel.

Albendazole has caused bone-marrow suppression in dogs and cats and is teratogenic; the label bans pregnancy, lactation, puppies under 3 weeks and debilitated or infected animals.

A measured liquid at 1 ml/kg suits puppies and toy breeds, and the label explains dilution for animals under 0.5 kg; the 10 ml bottle covers only small dogs.

The exact presentations are currently registered in Georgia and a current instruction plus a register-derived Russian record confirm identity, composition and labelled use. No EMA/FDA-style public assessment or transparent exact-product efficacy dossier was found; the available studies are old and use other aversectin combinations or routes, so the evidence gate applies.

Fipronil spot-on trials support ectoparasite activity and an older Avertel study supports the biological plausibility of aversectin C1 plus praziquantel against several endo- and ectoparasites. Neither source tests this exact topical triple combination, and the broad 6-7-week ectoparasite/helminth scope plus monthly heartworm prevention lacks robust independent exact-product trials.

The current instruction describes rare local reactions at the labelled dose but public target-animal safety data for the exact formulation are limited. Aversectin sensitivity, licking or overdose reactions, young/sick/debilitated patients, reproductive use, concurrent antiparasitics and environmental toxicity require explicit safeguards.

A whole weight-banded pipette makes dose selection straightforward and administration is a single topical event. Correct skin placement, prevention of licking, 48 hours without washing or close human contact and different general-parasite versus heartworm intervals add meaningful treatment burden.

The exact presentations are currently registered in Georgia and a current instruction plus a register-derived Russian record confirm identity, composition and labelled use. No EMA/FDA-style public assessment or transparent exact-product efficacy dossier was found; the available studies are old and use other aversectin combinations or routes, so the evidence gate applies.

Fipronil spot-on trials support ectoparasite activity and an older Avertel study supports the biological plausibility of aversectin C1 plus praziquantel against several endo- and ectoparasites. Neither source tests this exact topical triple combination, and the broad 6-7-week ectoparasite/helminth scope plus monthly heartworm prevention lacks robust independent exact-product trials.

The current instruction describes rare local reactions at the labelled dose but public target-animal safety data for the exact formulation are limited. Aversectin sensitivity, licking or overdose reactions, young/sick/debilitated patients, reproductive use, concurrent antiparasitics and environmental toxicity require explicit safeguards.

The two-pipette pack provides a clear 0.5 ml whole-pipette dose for cats 1-5 kg, but feline grooming makes placement and separation until dry important. The animal must remain unwashed for 48 hours, human contact is restricted for 48 hours and the prevention interval differs between general parasites and heartworm.

The exact presentations are currently registered in Georgia and a current instruction plus a register-derived Russian record confirm identity, composition and labelled use. No EMA/FDA-style public assessment or transparent exact-product efficacy dossier was found; the available studies are old and use other aversectin combinations or routes, so the evidence gate applies.

Fipronil spot-on trials support ectoparasite activity and an older Avertel study supports the biological plausibility of aversectin C1 plus praziquantel against several endo- and ectoparasites. Neither source tests this exact topical triple combination, and the broad 6-7-week ectoparasite/helminth scope plus monthly heartworm prevention lacks robust independent exact-product trials.

The current instruction describes rare local reactions at the labelled dose but public target-animal safety data for the exact formulation are limited. Aversectin sensitivity, licking or overdose reactions, young/sick/debilitated patients, reproductive use, concurrent antiparasitics and environmental toxicity require explicit safeguards.

A whole weight-banded pipette makes dose selection straightforward and administration is a single topical event. Correct skin placement, prevention of licking, 48 hours without washing or close human contact and different general-parasite versus heartworm intervals add meaningful treatment burden.

The exact presentations are currently registered in Georgia and a current instruction plus a register-derived Russian record confirm identity, composition and labelled use. No EMA/FDA-style public assessment or transparent exact-product efficacy dossier was found; the available studies are old and use other aversectin combinations or routes, so the evidence gate applies.

Fipronil spot-on trials support ectoparasite activity and an older Avertel study supports the biological plausibility of aversectin C1 plus praziquantel against several endo- and ectoparasites. Neither source tests this exact topical triple combination, and the broad 6-7-week ectoparasite/helminth scope plus monthly heartworm prevention lacks robust independent exact-product trials.

The current instruction describes rare local reactions at the labelled dose but public target-animal safety data for the exact formulation are limited. Aversectin sensitivity, licking or overdose reactions, young/sick/debilitated patients, reproductive use, concurrent antiparasitics and environmental toxicity require explicit safeguards.

A whole weight-banded pipette makes dose selection straightforward and administration is a single topical event. Correct skin placement, prevention of licking, 48 hours without washing or close human contact and different general-parasite versus heartworm intervals add meaningful treatment burden.

The exact presentations are currently registered in Georgia and a current instruction plus a register-derived Russian record confirm identity, composition and labelled use. No EMA/FDA-style public assessment or transparent exact-product efficacy dossier was found; the available studies are old and use other aversectin combinations or routes, so the evidence gate applies.

Fipronil spot-on trials support ectoparasite activity and an older Avertel study supports the biological plausibility of aversectin C1 plus praziquantel against several endo- and ectoparasites. Neither source tests this exact topical triple combination, and the broad 6-7-week ectoparasite/helminth scope plus monthly heartworm prevention lacks robust independent exact-product trials.

The current instruction describes rare local reactions at the labelled dose but public target-animal safety data for the exact formulation are limited. Aversectin sensitivity, licking or overdose reactions, young/sick/debilitated patients, reproductive use, concurrent antiparasitics and environmental toxicity require explicit safeguards.

A whole weight-banded pipette makes dose selection straightforward and administration is a single topical event. Correct skin placement, prevention of licking, 48 hours without washing or close human contact and different general-parasite versus heartworm intervals add meaningful treatment burden.